Add-back therapy in the treatment of endometriosis: the European experience

D K Edmonds, D. Keith Edmonds, Edmonds DK
British journal of obstetrics and gynaecology · 1996 · vol. 103 Suppl 14 , pp. 10–3 · PMID:8916980 · W2398902021
RCT OA: closed CC0 ⤵ 17 in-corpus citations
View on OpenAlex View on PubMed
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-08 ⓘ

European studies found that add-back hormone replacement therapy, including low-dose estradiol with medroxyprogesterone acetate or tibolone, significantly reduced bone mineral loss during GnRH agonist treatment for endometriosis without compromising efficacy.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Add-back hormone replacement therapy (HRT) can alleviate the undesirable hypo-oestrogenic effects of the gonadotrophin-releasing hormone (GnRH) agonists, including loss in bone mineral content. However, this approach presents a dilemma in patients with endometriosis as the re-introduction of oestrogen could re-stimulate the endometriotic process. There have been three recently published European studies investigating the combination of GnRH agonist plus add-back HRT in the treatment of endometriosis. The loss of bone mineral density was significantly diminished in a study using 25 micrograms oestradiol patches combined with continuous medroxyprogesterone acetate (5 mg). Neither this low oestrogen dose nor a full bone-sparing dose of oral oestradiol (2 mg daily) reduced the efficacy of Zoladex (goserelin acetate) in patients with endometriosis. Furthermore, in a small open study the gonadomimetic tibolone totally prevented the loss of bone structure during GnRH agonist therapy. If a GnRH agonist is considered the treatment of choice, then HRT should be used in combination.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Endometriosis Estradiol Estrogen Replacement Therapy Goserelin Medroxyprogesterone Acetate Norethindrone Administration, Cutaneous Administration, Cutaneous Bone Density Bone Density Double-Blind Method Double-Blind Method Drug Combinations Drug Combinations Endometriosis Endometriosis Estradiol Estradiol Estradiol Estradiol

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

Cited by (16)

Source provenance

europepmc
last seen: 2026-10-12T06:17:10.165071+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T22:00:02.201502+00:00
License: CC0 · commercial use OK